X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2024-11-07 | CRL | Charles River Laboratories International, Inc. | Wallman Richard F | Dir | S - Sale | $216.17 | -7,621 | 12,386 | -38% | -$1,647,418 | ||||||
| D | 2024-11-06 | INCY | Incyte Corp | Flannelly Barry P | EVP, GM US | S - Sale+OE | $79.68 | -3,680 | 58,042 | -6% | -$293,210 | |||||
| D | 2024-11-01 | MXCT | Maxcyte, Inc. | Erck Stanley C | Dir | S - Sale+OE | $3.72 | -47,689 | 269,118 | -15% | -$177,403 | |||||
| D | 2024-10-28 | MXCT | Maxcyte, Inc. | Johnston John Joseph | Dir | S - Sale+OE | $3.72 | -3,000 | 141,950 | -2% | -$11,166 | |||||
| DM | 2024-10-01 | MXCT | Maxcyte, Inc. | Erck Stanley C | Dir | S - Sale+OE | $3.75 | -47,689 | 269,118 | -15% | -$178,752 | |||||
| D | 2024-09-26 | MXCT | Maxcyte, Inc. | Johnston John Joseph | Dir | S - Sale+OE | $3.82 | -3,000 | 141,950 | -2% | -$11,460 | |||||
| M | 2024-09-12 | INCY | Incyte Corp | Tray Thomas | Principal Accounting Officer | S - Sale | $63.11 | -954 | 24,443 | -4% | -$60,209 | |||||
2024-09-12 | INCY | Incyte Corp | Dickinson Jonathan Elliott | EVP, GM, Europe | S - Sale | $62.36 | -8,450 | 36,390 | -19% | -$526,948 | ||||||
| DM | 2024-09-03 | MXCT | Maxcyte, Inc. | Erck Stanley C | Dir | S - Sale+OE | $4.02 | -47,689 | 269,118 | -15% | -$191,655 | |||||
2024-08-27 | IQV | Iqvia Holdings Inc. | Sherbet Eric | See Remarks | S - Sale | $246.33 | -1,300 | 19,536 | -6% | -$320,229 | ||||||
| D | 2024-08-26 | MXCT | Maxcyte, Inc. | Johnston John Joseph | Dir | S - Sale+OE | $4.28 | -3,000 | 141,950 | -2% | -$12,840 | |||||
| DM | 2024-08-22 | MEDP | Medpace Holdings, Inc. | Kraft Robert O. | Dir | S - Sale+OE | $390.73 | -8,127 | 520 | -94% | -$3,175,463 | |||||
2024-08-12 | INCY | Incyte Corp | Stein Steven H | EVP, Chief Medical Officer | S - Sale | $60.63 | -11,608 | 90,011 | -11% | -$703,793 | ||||||
2024-08-08 | CRL | Charles River Laboratories International, Inc. | Laplume Joseph W | EVP, Corp Strategy, Develop | S - Sale | $199.36 | -1,780 | 22,521 | -7% | -$354,861 | ||||||
| DM | 2024-08-01 | MXCT | Maxcyte, Inc. | Ross Thomas M. | EVP, GLOBAL SALES | S - Sale+OE | $4.44 | -33,333 | 25,000 | -57% | -$148,135 | |||||
2024-08-01 | CRL | Charles River Laboratories International, Inc. | Foster James C | COB, Pres, CEO | S - Sale | $250.00 | -25,000 | 238,854 | -9% | -$6,250,000 | ||||||
| D | 2024-07-26 | MXCT | Maxcyte, Inc. | Johnston John Joseph | Dir | S - Sale+OE | $4.75 | -3,000 | 141,950 | -2% | -$14,238 | |||||
2024-07-25 | INCY | Incyte Corp | Iyengar Vijay K | EVP, GMAPPS | S - Sale | $70.00 | -15,571 | 36,701 | -30% | -$1,089,970 | ||||||
2024-07-22 | FOXO | Foxo Technologies Inc. | Kr8 Ai Inc. | 10% | S - Sale | $0.25 | -1,300,000 | 0 | -100% | -$325,000 | ||||||
2024-07-22 | FOXO | Foxo Technologies Inc. | White Mark Brian | Interim CEO, 10% | S - Sale | $0.25 | -1,300,000 | 0 | -100% | -$325,000 | ||||||
2024-07-22 | FOXO | Foxo Technologies Inc. | Ward Martin Christopher | Interim CFO, 10% | S - Sale | $0.25 | -1,300,000 | 0 | -100% | -$325,000 | ||||||
| D | 2024-07-16 | INCY | Incyte Corp | Flannelly Barry P | EVP, GM US | S - Sale+OE | $64.19 | -1,306 | 58,042 | -2% | -$83,832 | |||||
2024-07-09 | INCY | Incyte Corp | Flannelly Barry P | EVP, GM US | S - Sale | $60.00 | -8,148 | 50,534 | -14% | -$488,880 | ||||||
| DM | 2024-07-08 | MXCT | Maxcyte, Inc. | Ross Thomas M. | EVP, GLOBAL SALES | S - Sale+OE | $4.03 | -33,333 | 25,000 | -57% | -$134,366 | |||||
| D | 2024-06-27 | MXCT | Maxcyte, Inc. | Johnston John Joseph | Dir | S - Sale+OE | $3.99 | -10,000 | 141,950 | -7% | -$39,900 | |||||
| D | 2024-06-20 | MXCT | Maxcyte, Inc. | Ross Thomas M. | EVP, GLOBAL SALES | S - Sale+OE | $4.09 | -33,333 | 25,000 | -57% | -$136,465 | |||||
| D | 2024-06-13 | ABSI | Absci Corp | Jonasson Zachariah | CFO , CBO | S - Sale+OE | $4.98 | -19,859 | 384,751 | -5% | -$98,892 | |||||
2024-06-12 | INCY | Incyte Corp | Flannelly Barry P | EVP, GM US | S - Sale | $60.00 | -19,164 | 66,377 | -22% | -$1,149,840 | ||||||
| M | 2024-06-07 | MXCT | Maxcyte, Inc. | Masoud Maher | Pres, CEO | P - Purchase | $4.89 | +100,000 | 100,000 | New | +$489,066 | |||||
2024-06-06 | INCY | Incyte Corp | Tray Thomas | Principal Accounting Officer | S - Sale | $58.91 | -1,093 | 21,634 | -5% | -$64,389 | ||||||
2024-06-05 | MEDP | Medpace Holdings, Inc. | Burwig Susan E | EVP, Operations | S - Sale | $401.20 | -7,681 | 7,500 | -51% | -$3,081,617 | ||||||
| AD | 2024-03-08 | CRL | Charles River Laboratories International, Inc. | Knell Michael Gunnar | CSVP, Chief Accounting Officer | S - Sale+OE | $267.52 | -808 | 7,825 | -9% | -$216,156 | |||||
| M | 2024-05-24 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | S - Sale | $395.38 | -9,682 | 5,387,675 | 0% | -$3,828,058 | |||||
2024-05-24 | OABI | Omniab, Inc. | Foehr Matthew W | Pres, CEO | P - Purchase | $4.42 | +240,000 | 3,536,665 | +7% | +$1,059,840 | ||||||
2024-05-22 | ABSI | Absci Corp | Phoenix Venture Partners II LP | 10% | S - Sale | $4.40 | -3,100,000 | 11,279,522 | -22% | -$13,640,000 | ||||||
2024-05-22 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | S - Sale | $400.00 | -55 | 5,397,357 | 0% | -$22,000 | ||||||
2024-05-20 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | S - Sale | $400.19 | -4,020 | 5,397,412 | 0% | -$1,608,764 | ||||||
| M | 2024-05-15 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | S - Sale | $404.76 | -39,342 | 5,401,432 | -1% | -$15,924,222 | |||||
2024-05-15 | CRL | Charles River Laboratories International, Inc. | Massaro George | Dir | S - Sale | $235.62 | -332 | 5,855 | -5% | -$78,225 | ||||||
2024-05-10 | CRL | Charles River Laboratories International, Inc. | Laplume Joseph W | EVP, Corp Strategy, Develop | S - Sale | $226.97 | -1,304 | 23,276 | -5% | -$295,969 | ||||||
2024-05-10 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | S - Sale | $402.89 | -4,956 | 5,440,774 | 0% | -$1,996,723 | ||||||
| M | 2024-05-08 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | S - Sale | $400.41 | -8,268 | 5,445,730 | 0% | -$3,310,566 | |||||
| M | 2024-05-06 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | S - Sale | $403.20 | -52,404 | 5,453,998 | -1% | -$21,129,347 | |||||
| M | 2024-05-01 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | S - Sale | $401.33 | -16,330 | 5,506,402 | 0% | -$6,553,671 | |||||
| M | 2024-04-29 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | S - Sale | $400.65 | -16,930 | 5,522,732 | 0% | -$6,782,987 | |||||
| D | 2024-04-08 | OABI | Omniab, Inc. | Gustafson Kurt A | EVP, Finance, CFO | S - Sale+OE | $5.27 | -6,954 | 176,697 | -4% | -$36,648 | |||||
| D | 2024-04-08 | OABI | Omniab, Inc. | Berkman Charles S | GC | S - Sale+OE | $5.27 | -6,954 | 292,617 | -2% | -$36,648 | |||||
| D | 2024-04-01 | OABI | Omniab, Inc. | Gustafson Kurt A | EVP, Finance, CFO | S - Sale+OE | $5.46 | -11,849 | 170,110 | -7% | -$64,696 | |||||
| D | 2024-03-26 | MXCT | Maxcyte, Inc. | Johnston John Joseph | Dir | S - Sale+OE | $4.41 | -5,000 | 120,583 | -4% | -$22,025 | |||||
2024-03-22 | OABI | Omniab, Inc. | Foehr Matthew W | Pres, CEO | P - Purchase | $5.19 | +225,000 | 2,908,803 | +8% | +$1,167,750 | ||||||
2024-03-15 | MEDP | Medpace Holdings, Inc. | Burwig Susan E | EVP, Operations | S - Sale | $403.00 | -102 | 15,181 | -1% | -$41,106 | ||||||
| D | 2024-03-14 | MEDP | Medpace Holdings, Inc. | Keating Ashley M. | Dir | S - Sale+OE | $409.87 | -250 | 250 | -50% | -$102,468 | |||||
2024-03-08 | CRL | Charles River Laboratories International, Inc. | Knell Michael Gunnar | CSVP, Chief Accounting Officer | S - Sale | $267.52 | -808 | 7,024 | -10% | -$216,156 | ||||||
| M | 2024-03-06 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | S - Sale | $411.61 | -200,000 | 5,539,662 | -3% | -$82,321,250 | |||||
| M | 2024-03-06 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | S - Sale | $411.61 | -200,000 | 4,733,019 | -4% | -$82,321,250 | |||||
| D | 2024-03-07 | MEDP | Medpace Holdings, Inc. | Keating Ashley M. | Dir | S - Sale+OE | $415.00 | -472 | 0 | -100% | -$195,880 | |||||
| D | 2024-03-04 | MEDP | Medpace Holdings, Inc. | Geiger Jesse J | Pres | S - Sale+OE | $403.03 | -22,321 | 21,503 | -51% | -$8,996,033 | |||||
| M | 2024-03-04 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | S - Sale | $402.91 | -100,000 | 5,739,662 | -2% | -$40,291,000 | |||||
| M | 2024-03-04 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | S - Sale | $402.91 | -100,000 | 4,933,019 | -2% | -$40,291,000 | |||||
2024-03-01 | ABSI | Absci Corp | Redmile Group, LLC | Dir | P - Purchase | $4.50 | +222,222 | 8,253,316 | +3% | +$999,999 | ||||||
2024-03-04 | CRL | Charles River Laboratories International, Inc. | Knell Michael Gunnar | CSVP, Chief Accounting Officer | S - Sale | $261.05 | -2,750 | 7,832 | -26% | -$717,890 | ||||||
2024-03-01 | NRC | National Research Corp | Common Property Trust | 10% | S - Sale | $40.54 | -598,653 | 3,854,284 | -13% | -$24,269,393 | ||||||
| D | 2024-03-01 | IQV | Iqvia Holdings Inc. | Bousbib Ari | See Remarks | S - Sale+OE | $250.53 | -31,678 | 1,328,885 | -2% | -$7,936,193 | |||||
2024-02-29 | IQV | Iqvia Holdings Inc. | Staub W Richard | See Remarks | S - Sale | $247.80 | -14,100 | 15,945 | -47% | -$3,494,034 | ||||||
| M | 2024-02-29 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | S - Sale | $400.25 | -100,000 | 5,033,019 | -2% | -$40,024,600 | |||||
| M | 2024-02-29 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | S - Sale | $400.25 | -100,000 | 5,839,662 | -2% | -$40,024,600 | |||||
2024-02-29 | CRL | Charles River Laboratories International, Inc. | Parisotto Shannon M | CEVP, Disc, Safety Assessment | S - Sale | $253.45 | -3,786 | 33,686 | -10% | -$959,545 | ||||||
2024-02-29 | CRL | Charles River Laboratories International, Inc. | Creamer Victoria L | EVP, Chief People Officer | S - Sale | $253.70 | -5,000 | 13,550 | -27% | -$1,268,500 | ||||||
| D | 2024-02-28 | IQV | Iqvia Holdings Inc. | Knightly Kevin C | See Remarks | S - Sale+OE | $250.17 | -8,607 | 652 | -93% | -$2,153,176 | |||||
| M | 2024-02-29 | MEDP | Medpace Holdings, Inc. | Ewald Stephen P | GC, Corp. Secy. | S - Sale | $395.19 | -1,513 | 13,341 | -10% | -$597,923 | |||||
2024-02-29 | MEDP | Medpace Holdings, Inc. | Geiger Jesse J | Pres | S - Sale | $393.51 | -2,558 | 3,824 | -40% | -$1,006,586 | ||||||
| D | 2024-02-28 | MEDP | Medpace Holdings, Inc. | Keating Ashley M. | Dir | S - Sale+OE | $405.00 | -500 | 0 | -100% | -$202,500 | |||||
| M | 2024-02-27 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | S - Sale | $403.01 | -100,000 | 5,133,019 | -2% | -$40,300,500 | |||||
| M | 2024-02-23 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | S - Sale | $401.07 | -156,928 | 6,039,662 | -3% | -$62,938,689 | |||||
| M | 2024-02-23 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | S - Sale | $401.07 | -156,928 | 5,233,019 | -3% | -$62,938,689 | |||||
2024-02-22 | CRL | Charles River Laboratories International, Inc. | Barbo William D | Corporate EVP, CCO | S - Sale | $248.50 | -4,050 | 26,914 | -13% | -$1,006,425 | ||||||
| M | 2024-02-21 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | S - Sale | $392.66 | -136,012 | 5,389,947 | -2% | -$53,406,441 | |||||
| M | 2024-02-21 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | S - Sale | $392.66 | -136,012 | 6,196,590 | -2% | -$53,406,441 | |||||
2024-02-16 | IQV | Iqvia Holdings Inc. | Sherbet Eric | See Remarks | S - Sale | $241.50 | -1,000 | 20,836 | -5% | -$241,500 | ||||||
| D | 2024-02-16 | IQV | Iqvia Holdings Inc. | Knightly Kevin C | See Remarks | S - Sale+OE | $241.10 | -13,468 | 652 | -95% | -$3,247,165 | |||||
| M | 2024-02-16 | MEDP | Medpace Holdings, Inc. | Medpace Investors, LLC | 10% | S - Sale | $390.58 | -63,988 | 5,525,959 | -1% | -$24,992,323 | |||||
| M | 2024-02-16 | MEDP | Medpace Holdings, Inc. | Troendle August J. | CEO, 10% | S - Sale | $390.58 | -63,988 | 6,332,602 | -1% | -$24,992,323 | |||||
| D | 2024-02-15 | CRL | Charles River Laboratories International, Inc. | Parisotto Shannon M | CEVP, Disc, Safety Assessment | S - Sale+OE | $241.21 | -5,882 | 37,884 | -13% | -$1,418,767 | |||||
2024-02-15 | CRL | Charles River Laboratories International, Inc. | Laplume Joseph W | EVP, Corp Strategy, Develop | S - Sale | $238.93 | -838 | 24,620 | -3% | -$200,223 | ||||||
2024-02-06 | FOXO | Foxo Technologies Inc. | Ward Martin Christopher | Interim CFO, 10% | S - Sale | $0.42 | -250,000 | 1,300,000 | -16% | -$105,000 | ||||||
2024-02-06 | FOXO | Foxo Technologies Inc. | White Mark Brian | Interim CEO, 10% | S - Sale | $0.42 | -250,000 | 1,300,000 | -16% | -$105,000 | ||||||
| D | 2024-01-26 | MXCT | Maxcyte, Inc. | Johnston John Joseph | Dir | S - Sale+OE | $5.12 | -5,000 | 120,583 | -4% | -$25,585 | |||||
2019-06-07 | NOTV | Inotiv, Inc. | Leasure Robert Jr. | Pres, CEO | P - Purchase | $1.98 | +7,500 | 146,434 | +5% | +$14,864 | ||||||
| M | 2024-01-04 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $40.85 | -7,214 | 4,755,317 | 0% | -$294,710 | |||||
2024-01-03 | NRC | National Research Corp | Common Property Trust | 10% | S - Sale | $41.53 | -364,625 | 4,452,937 | -8% | -$15,142,876 | ||||||
2024-01-03 | INCY | Incyte Corp | Stein Steven H | EVP, Chief Medical Officer | S - Sale | $65.51 | -7,365 | 90,218 | -8% | -$482,481 | ||||||
| M | 2024-01-02 | NRC | National Research Corp | Amandla Mk Trust | 10% | S - Sale | $40.86 | -321,239 | 4,762,531 | -6% | -$13,125,005 | |||||
2024-01-02 | INCY | Incyte Corp | Iyengar Vijay K | EVP, GMAPPS | S - Sale | $65.00 | -657 | 43,412 | -1% | -$42,705 | ||||||
| D | 2023-12-26 | MXCT | Maxcyte, Inc. | Johnston John Joseph | Dir | S - Sale+OE | $4.53 | -5,000 | 120,583 | -4% | -$22,650 | |||||
2023-12-21 | RNGE | Range Impact, Inc. | Cavanaugh Michael R. | CEO | P - Purchase | $0.15 | +1,000,000 | 1,879,791 | +114% | +$150,000 | ||||||
2023-12-21 | RNGE | Range Impact, Inc. | Feighan Edward F | Dir | P - Purchase | $0.15 | +666,667 | 3,690,917 | +22% | +$100,000 | ||||||
| M | 2023-12-14 | MEDP | Medpace Holdings, Inc. | Burwig Susan E | EVP, Operations | S - Sale | $303.96 | -12,400 | 15,283 | -45% | -$3,769,150 | |||||
| D | 2023-12-14 | CRL | Charles River Laboratories International, Inc. | Creamer Victoria L | EVP, Chief People Officer | S - Sale+OE | $225.00 | -5,526 | 16,506 | -25% | -$1,243,350 | |||||
| D | 2023-12-14 | NOTV | Inotiv, Inc. | Garrett Michael | Chief Commercial Officer | P - Purchase | $2.83 | +5,000 | 16,467 | +44% | +$14,145 | |||||
| D | 2023-12-14 | NOTV | Inotiv, Inc. | Beattie John Gregory | COO | P - Purchase | $3.12 | +47,966 | 111,761 | +75% | +$149,836 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |